1. Treatment outcomes of combination of anti-vascular endothelial growth factor injection and laser photocoagulation in Type 1 ROP and APROP
- Author
-
Parveen Sen, Suganeswari Ganesan, Aditi Ashok Kumar Agarwal, and Pramod Bhende
- Subjects
medicine.medical_specialty ,genetic structures ,Combination therapy ,Birth weight ,Posterior pole ,Angiogenesis Inhibitors ,Gestational Age ,Fundus (eye) ,Ophthalmology ,medicine ,Humans ,Retinopathy of Prematurity ,Retrospective Studies ,Retina ,Laser Coagulation ,business.industry ,Infant, Newborn ,Infant ,Gestational age ,Retrospective cohort study ,Retinopathy of prematurity ,medicine.disease ,eye diseases ,Treatment Outcome ,medicine.anatomical_structure ,Intravitreal Injections ,sense organs ,business - Abstract
To study treatment outcomes of combination treatment of intravitreal anti-vascular endothelial growth factor (VEGF) injection and laser photocoagulation in Type 1 Retinopathy of Prematurity (ROP) and Aggressive Posterior ROP (APROP). This is a retrospective observational study of 87 eyes of 48 premature babies who presented with Type I ROP or APROP and were treated with combination of laser and anti-VEGF therapy. Retrospective evaluation of case records was done to collect data on gestational age, birth weight, age at intervention, anterior segment and fundus findings, intervention with laser and anti-VEGF and response to treatment. Outcome measure was defined as attached retina at posterior pole at last follow-up. Mean gestational age was 29.1 weeks, and mean birth weight was 1226.9 gms. Sixty-six (75.8%) eyes had Type I ROP and 21 (24.1%) eyes had APROP at presentation. Five eyes (3 patients) were lost to follow-up after treatment. Of 82 eyes, 80.5% (66 eyes) showed regression of ROP following combination treatment and 19.5% (16 eyes) needed surgery. Of these, 15 underwent surgery and 12 had successful outcome. Mean follow-up duration of patients was 52 weeks. Finally, 95.1% (78 eyes) had attached retina at posterior pole and 4.9% (4 eyes) had detached retina. We conclude that combination therapy is an effective and safe treatment strategy for Type I ROP and APROP.
- Published
- 2021
- Full Text
- View/download PDF